Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : : A New Paradigm in Neuroblastoma / / written by Giorgia Centonze [and eight others].
Neuroblastoma, the most common extra-cranial pediatric solid tumor, is responsible for 9-15% of all pediatric cancer deaths. Its intrinsic heterogeneity makes it difficult to successfully treat, resulting in overall survival of 50% for half of the patients. Here we analyze the role in neuroblastoma...
Saved in:
VerfasserIn: | |
---|---|
Place / Publishing House: | London : : IntechOpen,, 2021. |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 online resource (130 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993581441204498 |
---|---|
ctrlnum |
(CKB)4920000002064509 (NjHacI)994920000002064509 (EXLCZ)994920000002064509 |
collection |
bib_alma |
record_format |
marc |
spelling |
Centonze, Giorgia, author. Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / written by Giorgia Centonze [and eight others]. Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression London : IntechOpen, 2021. 1 online resource (130 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on: online resource; title from PDF information screen (IntechOpen, viewed March 23, 2023). Neuroblastoma, the most common extra-cranial pediatric solid tumor, is responsible for 9-15% of all pediatric cancer deaths. Its intrinsic heterogeneity makes it difficult to successfully treat, resulting in overall survival of 50% for half of the patients. Here we analyze the role in neuroblastoma of the adaptor protein p140Cap, encoded by the SRCIN1 gene. RNA-Seq profiles of a large cohort of neuroblastoma patients show that SRCIN1 mRNA levels are an independent risk factor inversely correlated to disease aggressiveness. In high-risk patients, SRCIN1 was frequently altered by hemizygous deletion, copy-neutral loss of heterozygosity, or disruption. Functional assays demonstrated that p140Cap is causal in dampening both Src and Jak2 kinase activation and STAT3 phosphorylation. Moreover, p140Cap expression decreases in vitro migration and anchorage-independent cell growth, and impairs in vivo tumor progression, in terms of tumor volume and number of spontaneous lung metastasis. p140Cap also contributes to an increased sensitivity of neuroblastoma cells to chemotherapy drugs and to the combined usage of doxorubicin and etoposide with Src inhibitors. Overall, we provide the first evidence that SRCIN1/p140Cap is a new independent prognostic marker for patient outcome and treatment, with a causal role in curbing the aggressiveness of neuroblastoma. We highlight the potential clinical impact of SRCIN1/p140Cap expression in neuroblastoma tumors, in terms of reducing cytotoxic effects of chemotherapy, one of the main issues for pediatric tumor treatment. 1. Introduction -- 2. The p140Cap adaptor protein -- 3. SRCIN1 mRNA expression is an independent prognostic marker for NB -- 4. p140Cap negatively affects tumorigenic features -- 5. Molecular mechanisms and therapeutic targets in neuroblastoma -- 6. p140Cap impairs the Src/p130Cas and the STAT3/Jak2 signaling pathways -- 7. p140Cap increases NB cell sensitivity to chemotherapeutic treatment -- 8. p140Cap increases NB cell sensitivity to Src kinase inhibitors -- 9. Conclusions -- Acknowledgments -- Conflict of interest -- Rights and permissions -- Abbreviations -- References. Neuroblastoma. 1-83969-050-X |
language |
English |
format |
eBook |
author |
Centonze, Giorgia, |
spellingShingle |
Centonze, Giorgia, Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / 1. Introduction -- 2. The p140Cap adaptor protein -- 3. SRCIN1 mRNA expression is an independent prognostic marker for NB -- 4. p140Cap negatively affects tumorigenic features -- 5. Molecular mechanisms and therapeutic targets in neuroblastoma -- 6. p140Cap impairs the Src/p130Cas and the STAT3/Jak2 signaling pathways -- 7. p140Cap increases NB cell sensitivity to chemotherapeutic treatment -- 8. p140Cap increases NB cell sensitivity to Src kinase inhibitors -- 9. Conclusions -- Acknowledgments -- Conflict of interest -- Rights and permissions -- Abbreviations -- References. |
author_facet |
Centonze, Giorgia, |
author_variant |
g c gc |
author_role |
VerfasserIn |
author_sort |
Centonze, Giorgia, |
title |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / |
title_sub |
A New Paradigm in Neuroblastoma / |
title_full |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / written by Giorgia Centonze [and eight others]. |
title_fullStr |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / written by Giorgia Centonze [and eight others]. |
title_full_unstemmed |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / written by Giorgia Centonze [and eight others]. |
title_auth |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / |
title_alt |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression |
title_new |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : |
title_sort |
scaffold protein p140cap as a molecular hub for limiting cancer progression : a new paradigm in neuroblastoma / |
publisher |
IntechOpen, |
publishDate |
2021 |
physical |
1 online resource (130 pages) |
contents |
1. Introduction -- 2. The p140Cap adaptor protein -- 3. SRCIN1 mRNA expression is an independent prognostic marker for NB -- 4. p140Cap negatively affects tumorigenic features -- 5. Molecular mechanisms and therapeutic targets in neuroblastoma -- 6. p140Cap impairs the Src/p130Cas and the STAT3/Jak2 signaling pathways -- 7. p140Cap increases NB cell sensitivity to chemotherapeutic treatment -- 8. p140Cap increases NB cell sensitivity to Src kinase inhibitors -- 9. Conclusions -- Acknowledgments -- Conflict of interest -- Rights and permissions -- Abbreviations -- References. |
isbn |
1-83969-051-8 1-83969-050-X |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC280 |
callnumber-sort |
RC 3280 N4 C468 42021 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.9948 |
dewey-sort |
3616.9948 |
dewey-raw |
616.9948 |
dewey-search |
616.9948 |
work_keys_str_mv |
AT centonzegiorgia scaffoldproteinp140capasamolecularhubforlimitingcancerprogressionanewparadigminneuroblastoma AT centonzegiorgia scaffoldproteinp140capasamolecularhubforlimitingcancerprogression |
status_str |
n |
ids_txt_mv |
(CKB)4920000002064509 (NjHacI)994920000002064509 (EXLCZ)994920000002064509 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression : A New Paradigm in Neuroblastoma / |
_version_ |
1764995749100126208 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03202nam a2200301 i 4500</leader><controlfield tag="001">993581441204498</controlfield><controlfield tag="005">20230323202835.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230323s2021 enk o 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1-83969-051-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000002064509</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994920000002064509</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000002064509</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC280.N4</subfield><subfield code="b">.C468 2021</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.9948</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Centonze, Giorgia,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression :</subfield><subfield code="b">A New Paradigm in Neuroblastoma /</subfield><subfield code="c">written by Giorgia Centonze [and eight others].</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Scaffold Protein p140Cap as a Molecular Hub for Limiting Cancer Progression</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London :</subfield><subfield code="b">IntechOpen,</subfield><subfield code="c">2021.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (130 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from PDF information screen (IntechOpen, viewed March 23, 2023).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neuroblastoma, the most common extra-cranial pediatric solid tumor, is responsible for 9-15% of all pediatric cancer deaths. Its intrinsic heterogeneity makes it difficult to successfully treat, resulting in overall survival of 50% for half of the patients. Here we analyze the role in neuroblastoma of the adaptor protein p140Cap, encoded by the SRCIN1 gene. RNA-Seq profiles of a large cohort of neuroblastoma patients show that SRCIN1 mRNA levels are an independent risk factor inversely correlated to disease aggressiveness. In high-risk patients, SRCIN1 was frequently altered by hemizygous deletion, copy-neutral loss of heterozygosity, or disruption. Functional assays demonstrated that p140Cap is causal in dampening both Src and Jak2 kinase activation and STAT3 phosphorylation. Moreover, p140Cap expression decreases in vitro migration and anchorage-independent cell growth, and impairs in vivo tumor progression, in terms of tumor volume and number of spontaneous lung metastasis. p140Cap also contributes to an increased sensitivity of neuroblastoma cells to chemotherapy drugs and to the combined usage of doxorubicin and etoposide with Src inhibitors. Overall, we provide the first evidence that SRCIN1/p140Cap is a new independent prognostic marker for patient outcome and treatment, with a causal role in curbing the aggressiveness of neuroblastoma. We highlight the potential clinical impact of SRCIN1/p140Cap expression in neuroblastoma tumors, in terms of reducing cytotoxic effects of chemotherapy, one of the main issues for pediatric tumor treatment.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">1. Introduction -- 2. The p140Cap adaptor protein -- 3. SRCIN1 mRNA expression is an independent prognostic marker for NB -- 4. p140Cap negatively affects tumorigenic features -- 5. Molecular mechanisms and therapeutic targets in neuroblastoma -- 6. p140Cap impairs the Src/p130Cas and the STAT3/Jak2 signaling pathways -- 7. p140Cap increases NB cell sensitivity to chemotherapeutic treatment -- 8. p140Cap increases NB cell sensitivity to Src kinase inhibitors -- 9. Conclusions -- Acknowledgments -- Conflict of interest -- Rights and permissions -- Abbreviations -- References.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Neuroblastoma.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">1-83969-050-X</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-04-15 13:23:16 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-11-12 21:32:05 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5343040390004498&Force_direct=true</subfield><subfield code="Z">5343040390004498</subfield><subfield code="8">5343040390004498</subfield></datafield></record></collection> |